The stakes are more than semantic. Calling ET "neurodegenerative" implies a progressive loss of neurons with the prognostic and biological connotations that carries; calling it a "functional" or "oscillatory" disorder implies a potentially stable circuit dysfunction. The framing shapes how a clinician explains the condition, how the associated cognitive and non-motor features are understood, and where research effort is directed. It is also entangled with the modern classification of ET: the 2018 consensus explicitly treats ET as a syndrome rather than a single disease, leaving room for the possibility that different patients under the ET label have different underlying biology (Bhatia et al., Mov Disord, 2018).
The most influential argument for neurodegeneration comes from a program of postmortem study, principally from Columbia, contending that the anatomical pathology of ET — long elusive — is cerebellar and degenerative (Louis & Vonsattel, Mov Disord, 2008). The reported changes cluster in the cerebellar cortex and include Purkinje-cell loss, axonal torpedoes (swellings of the Purkinje-cell axon), dendritic and synaptic abnormalities, Bergmann gliosis, and heterotopic Purkinje cells. A distinctive quantitative marker in this literature is the "empty basket" — the interneuronal basket-cell axonal plexus that normally envelops a Purkinje-cell soma, left behind when that Purkinje cell is lost; empty baskets are reported to be increased in ET relative to controls and comparable to changes seen in other motor neurodegenerative diseases (Lee et al., J Neuropathol Exp Neurol, 2019). On this account, ET belongs alongside the recognized cerebellar degenerations, and its clinical evolution and non-motor features are the expected accompaniments of a progressive cerebellar process (Louis, Cerebellum, 2020).
Of these changes, the axonal torpedo has been the most consistently reported, and the proponents' broader argument is comparative: when the postmortem profile of ET is placed side by side with that of established cerebellar degenerations, the overlap in the type of change — Purkinje-cell pathology and its downstream effects on the surrounding circuitry — is offered as evidence that ET sits on the same spectrum rather than apart from it (Louis, Cerebellum, 2020). The strength of the case is its internal consistency across a large, systematically examined brain series; its vulnerability, addressed next, is whether the same changes are seen when other groups look.
The degenerative model is not universally accepted, and the central point of contention is replication. A controlled quantitative neuropathological study directly titled to the question found that ET is not dependent upon cerebellar Purkinje-cell loss: performing Purkinje-cell counts in ET brains alongside normal and Parkinson's-disease controls, it did not find the significant reduction the degenerative hypothesis predicts (Rajput et al., Parkinsonism Relat Disord, 2012). Critics of the degenerative model point to methodological heterogeneity across studies — differences in case ascertainment (tertiary-referral versus community brains), counting techniques, tissue handling, and the definition and quantification of torpedoes and empty baskets — as reasons the reported changes may be inconsistent, non-specific, or confounded. The unresolved status of even the foundational Purkinje-cell finding is why the "ET is a cerebellar degeneration" claim remains contested rather than established.
Several specific methodological fault lines run through the disagreement. Brain series drawn from tertiary referral centers may enrich for more severe or atypical cases and differ systematically from community-ascertained brains. Purkinje-cell quantification is sensitive to the counting method, the cerebellar region sampled, and correction for tissue shrinkage, so nominally comparable studies can reach opposite conclusions. And several of the signature changes are not specific to ET: torpedoes, some Purkinje-cell loss, and Bergmann gliosis occur with normal aging and in other conditions, so their mere presence does not establish a disease-defining degeneration. These are not fatal objections to the degenerative model, but they are the reason a single confirmatory finding has been hard to agree on.
A parallel body of work frames ET not as a disease of cell death but as a disorder of neurotransmission and abnormal oscillation. The leading version is the GABA hypothesis, which holds that impaired GABAergic inhibition is the core neurochemical lesion of ET, marshalling evidence across cerebrospinal-fluid, pathological, genetic, animal-model, imaging, computational, and pharmacological studies — while explicitly acknowledging negative studies and ongoing controversy (Gironell, Int Rev Neurobiol, 2022). Neurophysiological studies likewise demonstrate cerebellar dysfunction in ET without requiring frank degeneration, consistent with an abnormally oscillating cerebello-thalamo-cortical network (Hanajima et al., Mov Disord, 2016). In this view the cerebellum is central to ET — but as the site of a functional rhythmic disturbance rather than a wasting one, which would explain why tremor can be present for decades without the relentless deterioration typical of classic neurodegenerations.
The oscillatory framing has a long pedigree. The tremor of ET is understood as an abnormal rhythmic output of the cerebello-thalamo-cortical loop, with the inferior olive and its pacemaking properties long implicated as a potential rhythm generator — a mechanism that is fundamentally one of aberrant synchronization rather than neuronal loss (Welton et al., Nat Rev Dis Primers, 2021). The pharmacology of ET is broadly consistent with this: the agents that reduce it act on neuronal excitability and inhibition rather than on any degenerative process, which is more readily explained by a network-oscillation model than by cell death. None of this excludes structural change — a network can oscillate abnormally because a component has degenerated — but it does mean that the presence of a tremor, and even of cerebellar dysfunction on physiological testing, is not by itself evidence of degeneration (Hanajima et al., Mov Disord, 2016).
The most durable resolution may be that the dichotomy is false. Deuschl and Elble argued early that ET is best understood as a syndrome produced by more than one process: some cases show limited Lewy-body pathology, others show cerebellar changes with torpedoes and Bergmann gliosis, and the clinical picture spans additional cerebellar motor disturbances, cognitive and personality changes, and sensory deficits (Deuschl & Elble, Mov Disord, 2009). On this reading, asking whether "ET" is neurodegenerative is like asking whether "tremor" is — the label subsumes distinct entities, some of which may be degenerative and some not.
Much of the momentum behind the degenerative reframing came from the recognition that ET is not motorically isolated. The evidence that ET carries an elevated risk of cognitive impairment and dementia — more so with older onset — is one of the strongest clinical arguments that something more than a benign oscillation is at work (Cosentino & Shih, Int Rev Neurobiol, 2022). Mood disturbance, gait and balance findings, and sensory changes point the same way. Yet these associations are also compatible with a heterogeneous-syndrome model, in which the subset of patients with cognitive decline may be precisely those with a cerebellar-degenerative or mixed pathology — which is one reason the ET-plus category, defined partly by mild cognitive and cerebellar soft signs, sits so close to this debate (Bhatia et al., Mov Disord, 2018).
No consensus currently exists on whether ET is a neurodegenerative disease, and the honest position is to hold the question open. The foundational neuropathological claim — reduced Purkinje-cell number — is itself disputed (Rajput et al., Parkinsonism Relat Disord, 2012); the functional alternative is well-argued but lacks a single confirmed lesion (Gironell, Int Rev Neurobiol, 2022); and the comprehensive reviews of ET treat its pathophysiology as involving the cerebello-thalamo-cortical network while explicitly noting that the neurodegenerative question is unresolved (Welton et al., Nat Rev Dis Primers, 2021). For the clinician, the practical implications are modest but real: it is reasonable to tell patients that ET is more than "just a tremor" — that cognitive, mood, and other non-motor features are recognized associations — without over-committing to a degenerative narrative the evidence does not yet support. For the field, the debate is a spur toward the standardized neuropathology, imaging biomarkers, and longitudinal cohorts that could finally settle whether "essential tremor" names one disease, several, or a functional state that has been mistaken for a disease.